focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Shire Plc

7 Jan 2019 14:50

HBK Investments LP - Form 8.3 - Shire Plc

HBK Investments LP - Form 8.3 - Shire Plc

PR Newswire

London, January 7

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeShire Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure04 January 2019
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” YES: Takeda Pharmaceutical Company Limited

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:5p Ordinary (ISIN: JE00B2QKY057) ADR (ISIN: US82481R1068)
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled: 2,971,927 0.323 0.000
(2) Cash-settled derivatives: 26,543,314 2.891
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: 1,800,000 0.196 1,800,000 0.196
TOTAL: 31,315,241 3.410 1,800,000 0.196

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
ADRBuy464,348 (1,393,044 ordinary equivalent)USD 178.1000

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?YES

Date of disclosure:07 January 2019
Contact name:Jonathan Brown
Telephone number*:+44 (0)20 7659 1906

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Full name of person making disclosure:HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:Shire PLC

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant securityProduct description e.g. call optionWritten or purchasedNumber of securities to which option or derivative relatesExercise price per unitType e.g. American, European etc.Expiry date
ADRCall OptionWritten600,000 (1,800,000 ordinary equivalent)USD 200American18 Jan 2019
ADRCall OptionPurchased600,000 (1,800,000 ordinary equivalent)USD 185American18 Jan 2019

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
28th Dec 20181:38 pmBUSForm 8.3 - SHIRE PLC
28th Dec 201811:56 amRNSForm 8.5 (EPT/RI)- Shire plc AMENDMENT
28th Dec 201811:36 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
28th Dec 201811:28 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
28th Dec 201811:25 amRNSForm 8.3 - Shire plc replacement (2)
28th Dec 201811:24 amRNSForm 8.5 (EPT/NON-RI)
28th Dec 201811:24 amRNSForm 8.3 - Shire PLC
28th Dec 201811:23 amRNSForm 8.5 (EPT/NON-RI)
28th Dec 201811:23 amRNSForm 8.3 - Takeda Pharmaceutical
28th Dec 201811:15 amRNSForm 8.5 (EPT/RI)- Shire plc AMENDMENT
28th Dec 201811:13 amRNSForm 8.5 (EPT/RI)- Shire plc AMENDMENT
28th Dec 201811:12 amRNSForm 8.5 (EPT/RI)- Shire plc AMENDMENT
28th Dec 201811:12 amRNSForm 8.5 - Shire plc
28th Dec 201811:12 amRNSForm 8 (DD) - Shire plc
28th Dec 201811:03 amRNSForm 8.5 (EPT/RI) - Amendment
28th Dec 201811:03 amRNSForm 8.5 (EPT/RI) - Amendment
28th Dec 201810:58 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
28th Dec 201810:54 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
28th Dec 201810:54 amRNSForm 8.5 (EPT/RI)
28th Dec 201810:52 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
28th Dec 201810:51 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
28th Dec 201810:50 amRNSForm 8.5 (EPT/NON-RI)
28th Dec 201810:49 amRNSForm 8.5 (EPT/RI)
28th Dec 201810:45 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
28th Dec 201810:34 amRNSForm 8.5 (EPT/NON-RI) - SHIRE PLC
28th Dec 201810:13 amRNSForm 8.3 - Shire Plc
28th Dec 201810:11 amRNSForm 8.5 (EPT/RI)- Shire plc
28th Dec 20189:58 amBUSForm 8.3 - SHIRE PLC - Amendment
28th Dec 20189:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
28th Dec 20189:38 amRNSForm 8.3 - Shire plc
28th Dec 20187:00 amGNWHolding(s) in Company
28th Dec 20187:00 amGNWRule 2.9 Announcement
27th Dec 20185:19 pmRNSForm 8.3 - Shire plc
27th Dec 20184:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
27th Dec 20183:20 pmBUSForm 8.3 - Shire plc
27th Dec 20183:17 pmRNSForm 8.3 - Takeda Pharmaceutical
27th Dec 20183:15 pmRNSForm 8.3 - Shire plc replacement
27th Dec 20183:13 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
27th Dec 20183:10 pmBUSForm 8.3 - Shire plc
27th Dec 20183:08 pmBUSForm 8.3 - Shire plc
27th Dec 20183:07 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
27th Dec 20183:06 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
27th Dec 20183:00 pmRNSForm 8.3 - Shire plc
27th Dec 20182:54 pmRNSForm 8.5 (EPT/NON-RI)
27th Dec 20182:47 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
27th Dec 20182:37 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
27th Dec 20182:34 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
27th Dec 20182:30 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
27th Dec 20182:02 pmRNSForm 8.5 (EPT/NON-RI)
27th Dec 20181:42 pmRNSForm 8.3 - [Shire Plc]

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.